Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06164730 · ClinicalTrials.gov registry record · Phase 1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
A Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, sponsored by Verve Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 18
- Study locations
NCT06164730: Recruiting Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, sponsored by Verve Therapeutics.
NCT06164730 is a Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease that is actively recruiting participants, run by Verve Therapeutics. The registered enrollment target is 85 participants, below the 242-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (65% lower). The trial reports 18 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06164730, a Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, is actively recruiting participants, sponsored by Verve Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 18
- Study locations
Study Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Conditions Studied
Interventions
- DRUG VERVE-102
Study Locations (18)
Other
- Clinical Study Center - Adelaide
- Clinical Study Center - Melbourne
- Clinical Study Center - Sydney
- Clinical Study Center - Chicoutimi
- Clinical Study Center - Montreal
- Clinical Study Center - Toronto
- Clinical Study Center - Vancouver
- Clinical Study Center - Rehovot
- Clinical Study Center - Christchurch
- Clinical Study Center - Birmingham
- Clinical Study Center - Edinburgh
- Clinical Study Center - London
- Clinical Study Center - Manchester
- Clinical Study Center - Nottingham
Alabama
- Clinical Study Center - Dothan
North Carolina
- Clinical Study Center - High Point
Texas
- Clinical Study Center - DeSoto
Washington
- Clinical Study Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT06164730 shows while recruiting
NCT06164730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 242-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Heterozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which VERVE-102 is the first listed.
NCT06164730 lists 18 locations in 5 states (Other, Alabama, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06164730 about?
NCT06164730 is a clinical study titled "A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease". VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing...
What is the current status of trial NCT06164730?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2024-04-30. Estimated completion is 2027-08.
What conditions does trial NCT06164730 study?
This clinical trial studies the following conditions: Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease.
What interventions are being tested in trial NCT06164730?
The interventions under investigation include: VERVE-102 (DRUG).
Who is sponsoring clinical trial NCT06164730?
This trial is sponsored by Verve Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06164730 being conducted?
This trial has 18 study locations across Alabama, North Carolina, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heterozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
COMPLETED · Phase 3
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
COMPLETED · Phase 3
-
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI